Dendreon Corp fka DNDNQ

[walldiver]

Yes to the first question and not sure to the second. By late 2008, 50-60% of the patients will have been enrolled for two years or more, and about 30% for three years or more. The important additional stratification factor for 9902B's randomization is the number of bone mets, which was perhaps the greatest predictive factor for a given patient's survival in both 9901 and 9902A. It worked against the Provenge arm in both 9901 and 9902A, but in the latter trial to a greater extent. So that should help, along with the fact that Cox will be the primary analysis. It's still very far from a slam dunk on the interim.